Posts by James Louis Januzzi, MD
-
Cardiorenal Biomarkers Predict Major Complications in Patients With Type 2 Diabetes and Chronic Kidney Disease
James L. Januzzi, MD, and colleagues showed that among people with type 2 diabetes and albuminuria, baseline and follow-up concentrations of four biomarkers of cardiorenal stress individually and collectively predicted the risk of heart failure, progression of kidney disease, and related outcomes.
-
CAD Prevalent in Patients With Type 2 MI but Usually Non-obstructive
Cian P. McCarthy, MBBCh, BAO, SM, James L. Januzzi, Jr., MD, and colleagues found in a prospective study that coronary artery disease affected 92% of patients with type 2 myocardial infarction, but despite a large overall burden of coronary plaque, 74% did not have hemodynamically significant focal stenosis.
-
Multi-Biomarker Panel Predicts CV Events in Patients With Chronic Kidney Disease
For assessing patients with chronic kidney disease, James L. Januzzi, MD, Reza Mohebi, MD, and colleagues have developed a panel of four biomarkers that have different roles in the pathophysiology of cardiovascular disease and may be useful as a unique tool for predicting cardiovascular events.
-
Use of High-sensitivity Cardiac Troponin Assays Would Benefit U.S. Hospitals
As of September 2021, only 33% of U.S. hospitals used high-sensitivity cardiac troponin assays, Massachusetts General Hospital researchers found. Yet, the assays are linked to modestly shorter length of stay, no increase in in-hospital mortality, and less use of invasive angiography to evaluate low-risk chest pain.
-
Virtual Randomized Trial Feasible, Demonstrates Canagliflozin Relieves Symptom Burden in HF
James L. Januzzi, MD, and colleagues conducted a large randomized, placebo-controlled trial without any in-person visits, demonstrating canagliflozin was associated with a rapid and clinically meaningful improvement in the symptoms of heart failure regardless of ejection fraction and presence of diabetes.
-
Reverse Cardiac Remodeling May Underlie Benefit of Sacubitril/Valsartan in HFrEF
An exploratory analysis of the PROVE-HF trial of sacubitril/valsartan showed that reductions in biomarkers of myocardial injury correlate with improvements in cardiac remodeling in patients with chronic heart failure—and biomarkers may be capable of guiding short-term follow-up care.
-
Type 2 Myocardial Infarction Is Prevalent in U.S., Has a Distinct Clinical Profile
Cian P. McCarthy, MD, and James L. Januzzi, Jr., MD, of the Division of Cardiology, and colleagues found in a nationwide U.S. database study that type 2 myocardial infarction (MI) is common and patients have distinctly different characteristics and outcomes than those with type 1 MI.
-
TRANSFORM HFrEF Study Aims to Improve HF Outcomes
Massachusetts General Hospital Corrigan Minehan Heart Center investigators are transforming the outpatient experience for patients with HFrEF to achieve optimal guideline-directed medical therapy doses and improve outcomes.
-
Proteomics Can Detect Response to Heart Failure Treatment
Massachusetts General Hospital researchers have identified a set of proteins specific to heart failure that might help diagnose the disease, evaluate treatment response and identify drug targets.
-
Caution Needed When Interpreting BNP During Sacubitril/Valsartan Treatment
The effects of sacubitril/valsartan treatment on B-type natriuretic peptide vary in individual patients and according to the type of assay used.
-
Vericiguat Cuts Hospital Admissions in HFrEF Patients
The recent VICTORIA trial found that the novel oral agent vericiguat reduced mortality and hospitalization among recently decompensated heart failure with reduced ejection fraction (HFrEF) patients. The trial is the first to lower the risk of heart failure hospitalization in HFrEF patients.
-
The Impact of Troponin Levels on the Care of COVID-19 Patients
In this Q&A, James L. Januzzi, Jr, MD, of the Massachusetts General Hospital Corrigan-Minehan Heart Center, discusses cardiac injury in COVID-19 patients and what elevated troponin and other biomarker levels can tell providers about the prognosis and care of their patients.
-
Review: Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays
Myocardial injury carries a worse prognosis than MI and warrants a thorough evaluation for its underlying precipitant.
-
Review: Predicting Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction
Circulating biomarkers and data from novel imaging modalities may eventually be used as indicators of cardiac remodeling.
-
HDL Apolipoproteins May Identify Risk, Prognosis of CAD
Analysis of high-density lipoprotein (HDL) apolipoproteins, individually and together, identifies patients with coronary artery disease (CAD) and may be able to flag those at increased risk of cardiovascular death when CAD is present.
-
New AI Model Predicts Acute Kidney Injury After Angiography
Cardiologists at Massachusetts General Hospital have developed a model using artificial intelligence that predicts acute kidney injury in patients undergoing coronary angiography.
-
Hospitals Urged to Adopt High-Sensitivity Cardiac Troponin Assays
A cardiologist at Massachusetts General Hospital led an American College of Cardiology expert panel in recommending what medical systems should consider before implementing high-sensitivity cardiac troponin assays.
-
ACC 2019: A Media Roundup
At the 2019 ACC Annual Meeting, cardiologists from Massachusetts General Hospital presented and discussed research findings and advances in clinical care, such as predicting and preventing adverse cardiovascular events and optimizing patient care.
-
Dual-Biomarker Strategy Helps Identify Nonresponders to Cardiac Resynchronization
Measurement of two blood-based biomarkers can identify patients with heart failure that are at risk of nonresponse to cardiac resynchronization therapy and major adverse cardiovascular events afterward.
-
Extremely Sensitive Troponin Assay Predicts Impending Cardiovascular Events in Patients with Stable Chest Pain
Data from the PROMISE trial suggest that a "single-molecule counting" troponin assay might someday allow office-based assessment of which patients with stable chest pain are at short-term risk of major cardiovascular events and need aggressive diagnostic evaluation.
-
Mass General at #ACC19
The American College of Cardiology's (ACC) Annual Scientific Session and Expo is a global exchange for cardiovascular scientists and clinicians to discuss and debate the latest science and information. Several cardiologists from Massachusetts General Hospital play important roles within the ACC before, during and after the annual symposium. A few of them share their perspectives on what excites them most about being an integral part of the ACC and ACC.19.
-
Leveraging Social Media in Medicine
A group from the Massachusetts General Hospital Corrigan Minehan Heart Center discusses how they leverage social media as both practicing clinicians and active researchers.
-
ACC Provides Guidance to Cardiologists on Using SGLT2 Inhibitors and GLP-1RAs
A new Expert Consensus Decision Pathway from the American College of Cardiology urges cardiologists to consider sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists for all patients with type 2 diabetes who have atherosclerotic cardiovascular disease.
-
sST2 Has Independent Prognostic Value for Patients with Chronic Heart Failure
Soluble suppression of tumorigenesis-2 (sST2), a biomarker related to inflammation and fibrosis, is strongly and independently predictive of all-cause mortality, cardiovascular mortality and hospitalization in patients with chronic heart failure, according to a recent meta-analysis.
-
#AHA18 on Twitter: New Cholesterol Guidelines, the PIONEER-HF Trial and More
Health care professionals at this year’s American Heart Association's Scientific Sessions discussed late-breaking research, innovative treatment approaches and brand new guidelines. The conversations carried over from the podium and conference halls onto Twitter.
-
Position Paper: Distinguish Type 1 and Type 2 MI in Readmission Reduction Program
Noting the different patient characteristics, prognosis and management strategies for type 1 and type 2 myocardial infarction, cardiologists at Massachusetts General Hospital argue that the Medicare Hospital Readmission Reduction Program should not conflate the two.
-
Endothelin-1 Is a Prognostic Marker in Patients Undergoing Coronary Angiography
By measuring endothelin-1 via a blood test, cardiologists may someday be able to determine which patients with cardiovascular disease are at highest risk of heart failure, myocardial infarction and death.
-
Advancing Diagnostic Biomarkers for Cardiovascular Disease
James Januzzi, MD, director of the Dennis and Marilyn Barry Fellowship in Cardiology Research, discusses his team’s focus on the role of biomarker testing to diagnose the presence of cardiovascular disease and to establish prognosis or course of the disease.
-
Poster: A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive PAD
Peripheral artery disease (PAD) is underdiagnosed and undertreated. A need exists for alternative means for evaluating PAD. A Mass General team describes a novel method to predict angiographically significant PAD.
-
Implementation of New Troponin Tests Aids Diagnosis of MI
Novel troponin blood tests help identify myocardial infarction earlier. An expert at Massachusetts General gives guidance for successful implementation.
-
ACC.18: Eight Sessions to See
At the ACC.18 Scientific Session and Expo, physicians and researchers from Mass General's Corrigan Minehan Heart Center will present their world-leading research and innovative approaches. Here are the eight can't miss sessions and presentations.
-
Novel Biomarkers for Heart Failure Management
Multibiomarker panels that include emerging novel biomarkers could surmount limitations of natriuretic peptides alone to improve personalized heart failure (HF) care.
-
#AHA17 Video: Scientific Sessions in Summary
Mass General physicians presented on the podium, moderated sessions or showcased posters over 50 times at the American Heart Association 2017 Scientific Sessions. Some of them answered the question: “What was the most interesting topic presented at this year’s Scientific Sessions?"
-
Identifying Risk Factors for Type 2 Myocardial Infarction
In one of the first large systematic surveys of the frequency and implications of supply/demand-related Type 2 Myocardial Infarction, a suite of risk factors has been identified to help ensure patients receive proper care.
-
Tool Helps Guide Decision Making in Managing Anticoagulation in Nonvalvular Atrial Fibrillation
Managing anticoagulation in nonvalvular atrial fibrillation can be improved using the 2017 American College of Cardiology’s Expert Consensus Decision Pathway.
-
Novel Noninvasive Scoring System Predicts Presence of Obstructive CAD
Noninvasive models to predict the presence of coronary artery disease may help reduce the societal burden of CAD.
-
Opinion: Transitioning from Personalized to Precision Medicine for HF Patients
Heart failure specialists transition from outdated practice patterns to precision medicine and biomarker-based care to improve outcomes.
-
Advances in Heart Failure Management
Conventional strategies and emerging novel therapies offer clinicians a management suite to offset the rising toll from heart failure.
Biography
Dr. Januzzi has been a member of the Massachusetts General Hospital Cardiology Division since 2000 where he is the Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine. He is also the Hutter Family Professor of Medicine at Harvard Medical School and is on faculty at the Harvard Clinical Research Institute.
Dr. Januzzi graduated first in his class from New York Medical College in 1994, and subsequently did a residency in Internal Medicine at the Brigham and Women's Hospital, followed by a cardiology and echocardiography fellowship at Massachusetts General Hospital. Since joining the staff at Mass General, Dr. Januzzi is an active clinician, with a focus on acute myocardial infarction, chronic coronary artery disease, acute heart failure, chronic heart failure, and aortic disease. He is an active teacher, and has a busy research program, with a specific focus on cardiac biomarker testing. He has published more than 400 manuscripts, and has edited 3 textbooks, and speaks widely on the topic of biomarker testing in heart disease. He has served as the Cardiology Consultant to the Boston Red Sox since 2005.
